Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | OXTR | P30559 | 6/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224732 | 0.92 | OXTR (0.41) | TDP1OXTRAVPR1APRKAB2PRKAG1 | |
| SCHEMBL4596575 | 0.88 | TDP1 (0.42) | TDP1OXTRAVPR1APRKAB2PRKAG1 | |
| SCHEMBL6368626 | 0.88 | AQP1 (0.40) | OXTRAVPR1APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4219277 | 0.88 | OXTR (0.44) | OXTRAVPR1APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4226299 | 0.87 | OXTR (0.44) | OXTRAVPR1APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL6367712 | 0.87 | TDP1 (0.41) | TDP1OXTRAVPR1AALDH1A1LMNA | |
| SCHEMBL6047928 | 0.86 | OXTR (0.37) | TDP1OXTRAVPR1APRKAB2PRKAG1 | |
| SCHEMBL4234044 | 0.85 | PRKAB2 (0.44) | OXTRAVPR1APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4226073 | 0.85 | OXTR (0.52) | OXTRAVPR1APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4229060 | 0.84 | OXTR (0.39) | OXTRAVPR1APRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | HTR2C, HTR1A, HTR3A | TDP1 1482/4885OXTR 236/4885AVPR1A 122/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | TDP1 1482/4885OXTR 236/4885AVPR1A 122/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | TDP1 2315/4885OXTR 186/4885AVPR1A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.